Skip to main navigation Skip to search Skip to main content

A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome

  • Maria Juarez
  • , Nieves Diaz
  • , Geoffrey I. Johnston
  • , Saba Nayar
  • , Andrew Payne
  • , Eric Helmer
  • , Dionne Cain
  • , Paulette Williams
  • , Valerie Devauchelle-Pensec
  • , Benjamin A. Fisher
  • , Roberto Giacomelli
  • , Jacques Eric Gottenberg
  • , Giuliana Guggino
  • , Marika Kvarnström
  • , Xavier Mariette
  • , Wan Fai Ng
  • , José Rosas
  • , Juan Sánchez Bursón
  • , Giovanni Triolo
  • , Francesca Barone
    • Simon J. Bowman
  • UCB S.A.
  • University of Birmingham
  • Discovery Biology
  • Quantitative Clinical Pharmacology
  • Université de Bretagne Occidentale
  • University Hospitals Birmingham NHS Foundation Trust
  • University of L'Aquila
  • Strasbourg University Hospital
  • University of Palermo
  • Karolinska Institutet
  • Université Paris-Saclay
  • Newcastle University
  • Hospital Marina Baixa
  • Infanta Luisa Hospital

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry